Cargando…
Clinical application of thioredoxin reductase as a novel biomarker in liver cancer
Hepatic cancer is often amenable to surgery, including percutaneous ablation, trans-arterial chemoembolization. However, in metastatic cases, surgery is often not an effective option. Chemotherapy as a conventional clinical method for treatment of malignant diseases may be useful in such cases, but...
Autores principales: | Wu, Xuping, Wang, Qi, Lu, Yousheng, Zhang, Jinye, Yin, Hanwei, Yi, Yongxiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966739/ https://www.ncbi.nlm.nih.gov/pubmed/33727662 http://dx.doi.org/10.1038/s41598-021-85688-3 |
Ejemplares similares
-
Plasma activity of Thioredoxin Reductase as a Novel Biomarker in Gastric Cancer
por: Peng, Wei, et al.
Publicado: (2019) -
Author Correction: Plasma activity of Thioredoxin Reductase as a Novel Biomarker in Gastric Cancer
por: Peng, Wei, et al.
Publicado: (2020) -
Thioredoxin Reductase as a Novel and Efficient Plasma Biomarker for the Detection of Non-Small Cell Lung Cancer: a Large-scale, Multicenter study
por: Ye, Suofu, et al.
Publicado: (2019) -
Butaselen prevents hepatocarcinogenesis and progression through inhibiting thioredoxin reductase activity
por: Zheng, Xiaoqing, et al.
Publicado: (2017) -
Hepatocyte Hyperproliferation upon Liver-Specific Co-disruption of Thioredoxin-1, Thioredoxin Reductase-1, and Glutathione Reductase
por: Prigge, Justin R., et al.
Publicado: (2017)